GLPwatch
Trulicity for Depression
dulaglutide · Investigational / off-label
Last updated 2026-05-28 15:46 UTCTrulicity (dulaglutide) is not FDA-approved for treating depression, and any use for this condition is off-label or investigational. Research in mice suggests dulaglutide may reduce depression-like behaviors, while a database study reported psychiatric and psychological adverse effects associated with dulaglutide.
AI summary of the sources below.
| Drug | Trulicity (dulaglutide) |
|---|---|
| Condition | Depression |
| Approval status | Investigational / off-label |
| Research papers | 3 |
Trulicity is not FDA-approved for depression; the research below reflects investigational or off-label study only.
Research on dulaglutide for depression (3)
- Dulaglutide impedes depressive-like behavior persuaded by chronic social defeat stress model in male C57BL/6 mice: Implications on GLP-1R and cAMP/PKA signaling pathway in the hippocampus.
- Dulaglutide treatment reverses depression-like behavior and hippocampal metabolomic homeostasis in mice exposed to chronic mild stress.
- Psychiatric and psychological adverse effects associated with dulaglutide, semaglutide, and liraglutide: A vigibase study.